Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2015 48 146 M
EBIT 2015 16 949 M
Net income 2015 10 700 M
Debt 2015 10 753 M
Yield 2015 3,15%
Sales 2016 50 374 M
EBIT 2016 18 202 M
Net income 2016 12 070 M
Debt 2016 6 571 M
Yield 2016 3,36%
PER 2015 20,63
PER 2016 18,37
EV / Sales 2015 4,94x
EV / Sales 2016 4,64x
Capitalization 227 115 M
More Financials
Company
Roche Holding AG operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics.It operates business through two divisons: Pharmaceuticals and Diagnostics.The Pharmaceuticals divison comprises the two business segments Roche Pharmaceuticals and Chugai,... 
Sector
Pharmaceuticals
Calendar
09/09Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
08/24 AstraZeneca names Genentech's Bohen as chief medical officer
08/19DJRoche Buys U.S. Gene-Technology Company Kapa Biosystems
08/17 ROCHE : Pivotal Phase II Study Showed Genentech’s Investigational Immunoth..
08/13 Roche buys 'superbug' diagnostics firm for up to $425 million
08/13DJRoche Buys U.S. Company GeneWEAVE BioSciences Inc.
08/12 ROCHE : Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primar..
08/05 Shire seen having to sweeten $30 billion offer to win Baxalta
08/03 Analysis - New cocktails to test limits of cancer drug pricing
More news
Sector news : Pharmaceuticals - NEC
09:02a SANOFI : to Collaborate with Google Life Sciences to Improve Diabetes Health Out..
08:31a BIOMARIN PHARMACEUTICAL : Announces Two Oral and 19 Poster Presentations at the ..
08:31a BRISTOL MYERS SQUIBB : Enters Agreement Providing Exclusive Right to Acquire Pro..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions